Nabriva Therapeutics Added to NASDAQ Biotechnology Index

DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Dec. 13, 2017 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class

READ FULL TEXT

Leave a Reply

Your email address will not be published.